Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
PMV Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PMVP
Nasdaq
8731
https://www.pmvpharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for PMV Pharmaceuticals Inc
PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
- Apr 19th, 2024 11:58 am
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
- Mar 27th, 2024 12:00 pm
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
- Mar 18th, 2024 8:01 pm
PMV Pharmaceuticals Inc (PMVP) Reports Full Year 2023 Financial Results
- Mar 1st, 2024 3:21 pm
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
- Feb 29th, 2024 9:01 pm
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
- Feb 26th, 2024 1:00 pm
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
- Jan 18th, 2024 9:01 pm
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
- Jan 5th, 2024 9:01 pm
PMV Pharmaceuticals Inc (PMVP) Reports Q3 2023 Financial Results and Corporate Updates
- Nov 9th, 2023 2:41 pm
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
- Nov 9th, 2023 1:00 pm
PMV Pharmaceuticals, Inc. (PMVP) Loses -70.19% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Oct 16th, 2023 1:35 pm
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
- Oct 12th, 2023 4:30 pm
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
- Oct 11th, 2023 4:00 pm
Wall Street Analysts See a 239.26% Upside in PMV Pharmaceuticals, Inc. (PMVP): Can the Stock Really Move This High?
- Oct 6th, 2023 1:55 pm
We're Not Very Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Rate
- Sep 21st, 2023 4:44 pm
PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Sep 20th, 2023 8:05 pm
Wall Street Analysts Think PMV Pharmaceuticals, Inc. (PMVP) Could Surge 182.64%: Read This Before Placing a Bet
- Aug 30th, 2023 1:55 pm
PMV Pharmaceuticals, Inc. (PMVP)'s Technical Outlook is Bright After Key Golden Cross
- Aug 29th, 2023 1:55 pm
PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
- Aug 9th, 2023 12:00 pm
PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
- Jun 6th, 2023 8:01 pm
Scroll